Advertisement

Paper Retracted Following Lawsuit

Research funded in part by a biotech was retracted after a lawsuit claiming the work could not be replicated.

By | January 5, 2012

Prostate CancerWIKIMEDIA COMMONS, NEPHRON

Robert Getzenberg of Johns Hopkins University retracted his finding published in Urology on a novel blood protein that could be developed into a test for prostate cancer, after reviewing the original data and finding inconsistencies in the reported results.

The research had come under scrutiny because Onconome, a company that had in part funded the work, tried to develop the results into a diagnostic and failed, reported ScienceInsider.  They found that the biomarker was "essentially as reliable as flipping a coin," according to the Onconome’s lawsuit against Johns Hopkins, Getzenberg, and Getzenberg’s former employer, the University of Pittsburgh.

While the lawsuit was settled in 2010, the research was only retracted in October 2011, after it had been cited 67 times, according to Retraction Watch.

(Read more about the problem with cancer biomarkers.)

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: jhnycmltly

jhnycmltly

Posts: 65

January 8, 2012

At least someone caught THIS 'test for cancer'. It wasn't too long ago there was a test being USED that was found to be veritably useless.

Avatar of:

Posts: 0

January 8, 2012

At least someone caught THIS 'test for cancer'. It wasn't too long ago there was a test being USED that was found to be veritably useless.

Avatar of:

Posts: 0

January 8, 2012

At least someone caught THIS 'test for cancer'. It wasn't too long ago there was a test being USED that was found to be veritably useless.

Advertisement

Popular Now

  1. Most Earth-like Planet Found
  2. AAAAA Is for Arrested Translation
  3. Four-legged Snake Fossil Found
  4. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

Advertisement
Advertisement